Where I see patients (2)
Selected research
-
HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL.
Blood advances
-
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Blood
-
Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.
Blood
Clinical trials
Venetoclax Basket Trial for High Risk Hematologic Malignancies
To determine the maximum tolerated dose (MTD of venetoclax given in combination with regimen-prescribed chemotherapy. The MTD is defined as the dose level associated with observed DLTs in <33% of enrolled subjects
Recruiting
More about this studyA Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Mye...
The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.
Recruiting
More about this studyContact me
Fetal surgery firsts
The first open fetal surgery in the world was performed at UCSF in the early 1980s.
